AbbVie

News

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Patients in England with chronic lymphocytic leukaemia (CLL) will be able to access a new combination therapy based on Johnson & Johnson’s Imbruvica plus AbbVie’s Venc

News

AbbVie gets key FDA OK for migraine drug Qulipta

AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine.

News

FDA rejects AbbVie’s continuous Parkinson’s therapy

Delay could narrow the gap between AbbVie's product and a rival system from Mitsubishi Tanabe.

News

$AbbVie’s Skyrizi hits the spot in refractory psoriasis$

AbbVie’s Skyrizi hits the spot in refractory psoriasis

Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.

News

Pfizer’s migraine push builds with Zavzpret nod

Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.

News

AbbVie's Humira finally faces biosimilar challenge in US

AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after

NICE says yes to J&J, AbbVie first-line leukaemia regimen

AbbVie gets key FDA OK for migraine drug Qulipta

FDA rejects AbbVie’s continuous Parkinson’s therapy

AbbVie’s Skyrizi hits the spot in refractory psoriasis

Pfizer’s migraine push builds with Zavzpret nod

AbbVie's Humira finally faces biosimilar challenge in US

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

AbbVie

Editor's Picks